Oct 4, 2021 | Anti-METH antibody, IXT-m200, General News, Grants
Grant fully funds clinical trial, to be called “OUTLAST”, which will initiate in early 2022 LITTLE ROCK, AR, USA, October 4, 2021 /EINPresswire.com/ — InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today announced the award of additional...
Sep 21, 2021 | Anti-METH antibody, IXT-m200, General News
LITTLE ROCK, AR, USA, September 20, 2021 – InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today announced the enrollment of the first patient in Meth-OD, a Phase 2 study of the first-in-class anti-methamphetamine antibody IXT-m200 in...
Apr 19, 2021 | Anti-METH antibody, IXT-m200, General News
IXT-m200 produced significant changes in primary endpoint of methamphetamine pharmacokinetics, with favorable data for secondary endpoints and safety LITTLE ROCK, AR, USA, April 19, 2021 – InterveXion Therapeutics, a private clinical-stage biopharmaceutical...
Oct 5, 2020 | Anti-METH antibody, IXT-m200, General News, Grants
“Meth-OD” trial will be first known clinical trial specifically for patients suffering from methamphetamine overdose LITTLE ROCK, ARKANSAS, USA, October 5, 2020 /EINPresswire.com/ — InterveXion Therapeutics, a clinical-stage biopharmaceutical...
May 5, 2020 | Anti-METH antibody, IXT-m200, Grants
Grant fully funds manufacture of clinical supplies for Phase 2b clinical study and supports initiation of development of new subcutaneous formulation of IXT-m200 Little Rock, AR (01 May 2020) – InterveXion Therapeutics, a private clinical-stage biopharmaceutical...
Feb 6, 2020 | Anti-METH antibody, IXT-m200
Source: Part 2: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse...
Recent Comments